Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Edesa Biotech stock | $5.2

Own Edesa Biotech stock in just a few minutes.

Fact checked

Edesa Biotech, Inc is a biotechnology business based in the US. Edesa Biotech shares (EDSA) are listed on the NASDAQ and all prices are listed in US Dollars. Edesa Biotech employs 12 staff and has a trailing 12-month revenue of around USD$328,801.

How to buy shares in Edesa Biotech

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Edesa Biotech. Find the stock by name or ticker symbol: EDSA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Edesa Biotech reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$5.2, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Edesa Biotech, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Edesa Biotech. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Edesa Biotech share price

Use our graph to track the performance of EDSA stocks over time.

Edesa Biotech shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$5.2
52-week rangeUSD$1.58 - USD$10.15
50-day moving average USD$5.1109
200-day moving average USD$6.2387
Wall St. target priceUSD$15.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-5.794

Buy Edesa Biotech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Forex
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Edesa Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Edesa Biotech price performance over time

Historical closes compared with the close of $5.2 from 2020-12-18

1 week (2021-01-14) 5.05%
1 month (2020-12-24) 8.56%
3 months (2020-10-22) -19.50%
6 months (2020-07-22) -2.44%
1 year (2020-01-22) 54.81%
2 years (2019-01-22) 352.17%
3 years (2018-01-22) 471.18%
5 years (2016-01-22) 5.47

Edesa Biotech financials

Revenue TTM USD$328,801
Gross profit TTM USD$311,200
Return on assets TTM -48.55%
Return on equity TTM -88.61%
Profit margin 0%
Book value $0.564
Market capitalisation USD$50 million

TTM: trailing 12 months

Shorting Edesa Biotech shares

There are currently 24,632 Edesa Biotech shares held short by investors – that's known as Edesa Biotech's "short interest". This figure is 13.7% down from 28,530 last month.

There are a few different ways that this level of interest in shorting Edesa Biotech shares can be evaluated.

Edesa Biotech's "short interest ratio" (SIR)

Edesa Biotech's "short interest ratio" (SIR) is the quantity of Edesa Biotech shares currently shorted divided by the average quantity of Edesa Biotech shares traded daily (recently around 107095.65217391). Edesa Biotech's SIR currently stands at 0.23. In other words for every 100,000 Edesa Biotech shares traded daily on the market, roughly 230 shares are currently held short.

However Edesa Biotech's short interest can also be evaluated against the total number of Edesa Biotech shares, or, against the total number of tradable Edesa Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Edesa Biotech's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Edesa Biotech shares in existence, roughly 0 shares are currently held short) or 0.0048% of the tradable shares (for every 100,000 tradable Edesa Biotech shares, roughly 5 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Edesa Biotech.

Find out more about how you can short Edesa Biotech stock.

Edesa Biotech share dividends

We're not expecting Edesa Biotech to pay a dividend over the next 12 months.

Have Edesa Biotech's shares ever split?

Edesa Biotech's shares were split on a 1:6 basis on 10 June 2019. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Edesa Biotech shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Edesa Biotech shares which in turn could have impacted Edesa Biotech's share price.

Edesa Biotech overview

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site